PAI's Ethypharm bolts on Pharmy II Laboratory

The acquisition will enable Ethypharm to expand its portfolio with six new drugs and pharmaceutical specialties in injectable and liquid form.

Ethypharm develops and markets speciality and over-the-counter drugs with a focus on developing medicines for the treatment of pain and addiction. The business generated a €333m turnover in 2018 and has 1,400 employees mainly in Europe. Its drugs are marketed in around 80 countries.

PAI acquired the French drug maker Ethypharm from Astorg Partners in a deal reportedly valued at €725m in 2016. The GP used its €3.3bn Europe VI vehicle for the transaction. 

Since then, Ethypharm bolted on UK-based group Martindale Pharma in 2017.

Company
Founded in 1982 and based in Saint-Germain-en-Laye, Pharmy II Laboratory is a pharmaceutical laboratory. It specialises in the treatment of pain, particularly mechanical musculo-articular pain, and provides a range of products designed to be injected locally, using the mesotherapy technique. 

People
Ethypharm Group – Bertrand Deluard (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Portfolio management
• France
• Healthcare
• France
• PAI Partners
• Build-up